Carisma Therapeutics Inc Financials
Carisma Therapeutics Inc (CARM) reported $19.6M in revenue for fiscal year 2024, up 31.5% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Carisma’s business mechanics are still set by research spending and cash burn, with revenue too small to fund operations.
In FY2024, operating cash flow of-$59.9M was almost identical to net loss of-$60.5M , which means the accounting loss translated into real cash use rather than being softened by working-capital releases or large non-cash credits. Even though reported losses improved from FY2023, cash on hand fell to$17.9M from$77.6M , so the company became less funded even as earnings looked somewhat better.
R&D spending of
Overhead tightening is visible because SG&A dropped to
Financial Health Signals
Carisma Therapeutics Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Carisma Therapeutics Inc passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
Carisma Therapeutics Inc reported a net loss of $60.5M while operations used $59.9M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Carisma Therapeutics Inc generated $19.6M in revenue in fiscal year 2024. This represents an increase of 31.5% from the prior year.
Carisma Therapeutics Inc's EBITDA was -$58.8M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 31.5% from the prior year.
Carisma Therapeutics Inc reported -$60.5M in net income in fiscal year 2024. This represents an increase of 30.4% from the prior year.
Carisma Therapeutics Inc earned -$1.46 per diluted share (EPS) in fiscal year 2024. This represents an increase of 43.6% from the prior year.
Cash & Balance Sheet
Carisma Therapeutics Inc recorded an outflow of $60.0M in free cash flow in fiscal year 2024, representing a cash shortfall after capex. This represents an increase of 27.1% from the prior year.
Carisma Therapeutics Inc held $17.9M in cash as of fiscal year 2024; long-term debt is not reported for that period.
Not reported for fiscal year 2024.
Margins & Returns
Not reported for fiscal year 2024.
Not shown for fiscal year 2024: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for fiscal year 2024: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not reported for fiscal year 2024.
Capital Allocation
Carisma Therapeutics Inc invested $59.7M in research and development in fiscal year 2024. This represents a decrease of 19.5% from the prior year.
Carisma Therapeutics Inc invested $123K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 89.1% from the prior year.
Not reported for fiscal year 2024.
CARM Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | $19.6M+31.5% | $14.9M+52.0% | $9.8M-63.1% | $26.5M+136.2% | $11.2M | $0 | $0-100.0% | $425K+4.7% | $406K-17.1% | $490K-78.2% | $2.2M+68.1% | $1.3M | N/A |
| R&D Expenses | $27.4M | $59.7M-19.5% | $74.1M+30.9% | $56.6M+123.7% | $25.3M-13.3% | $29.2M+18.4% | $24.7M+75.2% | $14.1M+12.5% | $12.5M-7.2% | $13.5M-48.8% | $26.3M-1.4% | $26.7M+93.7% | $13.8M-9.7% | $15.3M |
| SG&A Expenses | $14.4M | $22.1M-25.0% | $29.5M+214.8% | $9.4M-68.1% | $29.4M+105.5% | $14.3M+17.2% | $12.2M+5.0% | $11.6M+44.0% | $8.1M-45.2% | $14.7M+49.6% | $9.8M+16.3% | $8.5M+110.5% | $4.0M-4.5% | $4.2M |
| Operating Income | $10.8M | -$62.2M+29.9% | -$88.7M-58.0% | -$56.2M-556.9% | -$8.5M+59.4% | -$21.1M+80.6% | -$108.5M-214.5% | -$34.5M-17.9% | -$29.3M-1120.8% | $2.9M+108.1% | -$35.2M-6.9% | -$32.9M-99.8% | -$16.5M+15.4% | -$19.5M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $0 | $0-100.0% | $991K | N/A |
| Income Tax | N/A | N/A | N/A | -$3.9M+53.2% | -$8.3M-672.5% | $1.4M | $0 | $0 | $0-100.0% | $5K | $0 | $0 | N/A | N/A |
| Net Income | $8.0M | -$60.5M+30.4% | -$86.9M-41.9% | -$61.2M-18122.0% | -$336K+98.5% | -$22.4M+79.2% | -$107.5M-219.1% | -$33.7M-16.1% | -$29.0M-1635.1% | $1.9M+105.7% | -$33.5M+2.1% | -$34.2M-89.5% | -$18.0M+8.3% | -$19.7M |
| EPS (Diluted) | — | -$1.46+43.6% | -$2.59 | -$28.77 | $0.00+100.0% | -$0.19+83.9% | -$1.18-114.5% | -$0.55 | -$1.11-1333.3% | $0.09+105.1% | -$1.76+25.7% | -$2.37 | N/A | N/A |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.
TTM is the trailing twelve months, Q4 FY2024 through Q3 FY2025, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
CARM Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $30.5M-66.0% | $89.6M+24.1% | $72.2M-70.0% | $240.7M+96.0% | $122.8M+7.4% | $114.4M+2.5% | $111.6M+48.6% | $75.1M-27.9% | $104.1M+182.7% | $36.8M-33.0% | $55.0M+389.5% | $11.2M | N/A |
| Current Assets | $23.8M-70.4% | $80.5M+47.4% | $54.6M-73.4% | $205.6M+227.0% | $62.9M+15.5% | $54.4M+5.2% | $51.8M+245.5% | $15.0M-42.2% | $25.9M-28.6% | $36.3M-33.3% | $54.4M+577.5% | $8.0M | N/A |
| Cash & Equivalents | $17.9M-76.9% | $77.6M+220.8% | $24.2M-85.1% | $162.6M+210.4% | $52.4M+8.9% | $48.1M-4.6% | $50.4M+243.5% | $14.7M-42.1% | $25.3M-29.8% | $36.1M-33.3% | $54.1M+580.7% | $7.9M+0.8% | $7.9M |
| Accounts Receivable | N/A | N/A | $0-100.0% | $21.0M | $0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | $0-100.0% | $13.1M0.0% | $13.1M0.0% | $13.1M0.0% | $13.1M0.0% | $13.1M-22.5% | $16.9M | $0 | N/A | N/A | N/A |
| Total Liabilities | $58.4M-7.4% | $63.0M-72.5% | $229.2M+232.0% | $69.0M-47.7% | $132.1M-6.4% | $141.1M+109.4% | $67.4M+18.0% | $57.1M-12.8% | $65.4M+265.9% | $17.9M-1.6% | $18.2M-72.3% | $65.6M | N/A |
| Current Liabilities | $16.1M+0.9% | $15.9M-19.1% | $19.7M+70.0% | $11.6M-35.9% | $18.0M+111.9% | $8.5M+39.3% | $6.1M+29.5% | $4.7M+18.6% | $4.0M-47.5% | $7.6M+45.7% | $5.2M-2.8% | $5.4M | N/A |
| Total Equity | -$27.9M-205.2% | $26.5M+116.9% | -$157.1M-191.5% | $171.7M+1961.0% | -$9.2M+65.4% | -$26.7M-160.4% | $44.2M+145.1% | $18.0M-53.4% | $38.7M+104.2% | $18.9M-48.6% | $36.8M+167.8% | -$54.3M-38.3% | -$39.3M |
| Retained Earnings | -$305.6M-24.7% | -$245.1M-54.9% | -$158.2M+50.0% | -$316.3M-0.1% | -$315.9M-7.6% | -$293.5M-57.8% | -$186.0M-22.1% | -$152.3M-23.5% | -$123.3M+1.5% | -$125.2M-36.5% | -$91.8M-59.3% | -$57.6M | N/A |
Not reported in any period shown, so not listed: Inventory, Long-Term Debt.
CARM Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$22.4M | -$59.9M+26.2% | -$81.2M-1486.7% | -$5.1M+92.6% | -$68.9M-123.4% | -$30.8M+17.8% | -$37.5M-64.4% | -$22.8M-28.5% | -$17.8M-800.0% | $2.5M+107.4% | -$34.5M-17.8% | -$29.3M-117.2% | -$13.5M+29.3% | -$19.1M |
| Capital Expenditures | $0 | $123K-89.1% | $1.1M-75.7% | $4.7M+116400.0% | $4K-50.0% | $8K-94.1% | $136K+6700.0% | $2K-80.0% | $10K | N/A | $287K+109.5% | $137K | $0-100.0% | $110K |
| Free Cash Flow | -$22.4M | -$60.0M+27.1% | -$82.3M-741.9% | -$9.8M+85.8% | -$68.9M-123.3% | -$30.8M+18.1% | -$37.7M-64.9% | -$22.8M-28.4% | -$17.8M | N/A | -$34.8M-18.2% | -$29.4M-118.2% | -$13.5M+29.7% | -$19.2M |
| Investing Cash Flow | $687K | -$123K-100.2% | $72.4M+322.4% | -$32.6M-813900.0% | -$4K+50.0% | -$8K+94.1% | -$136K-6700.0% | -$2K-102.0% | $98K-78.7% | $461K+260.6% | -$287K | N/A | N/A | N/A |
| Financing Cash Flow | -$2.4M | $344K-99.4% | $62.2M+86.6% | $33.3M-81.1% | $176.1M+362.1% | $38.1M+7.8% | $35.4M-39.6% | $58.6M+736.3% | $7.0M+150.7% | -$13.8M-182.1% | $16.8M | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $5K |
Not reported in any period shown, so not listed: Dividends Paid.
TTM is the trailing twelve months, Q4 FY2024 through Q3 FY2025, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
CARM Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -317.2% | -595.5% | -573.1% | -32.2% | -187.6% | N/A | N/A | -6883.5% | 705.9% | -7182.9% | -1468.2% | -1235.2% | N/A |
| Net Margin | -308.6% | -583.1% | -624.8% | -1.3% | -199.3% | N/A | N/A | -6830.4% | 465.8% | -6826.9% | -1522.8% | -1351.2% | N/A |
| Return on Equity | N/A | -327.5% | N/A | -0.2% | N/A | N/A | -76.2%+84.7pp | -161.0%-165.9pp | 4.9%+181.5pp | -176.6%-83.8pp | -92.8% | N/A | N/A |
| Return on Assets | -198.6%-101.6pp | -97.0%-12.1pp | -84.9%-84.7pp | -0.1%+18.1pp | -18.2%+75.8pp | -94.0%-63.8pp | -30.2%+8.5pp | -38.7%-40.5pp | 1.8%+92.7pp | -90.8%-28.7pp | -62.1%+98.3pp | -160.4% | N/A |
| Current Ratio | 1.48-3.6x | 5.06+2.3x | 2.78-15.0x | 17.77+14.3x | 3.48-2.9x | 6.39-2.1x | 8.47+5.3x | 3.17-3.3x | 6.51+1.7x | 4.79-5.7x | 10.46+9.0x | 1.50 | N/A |
| Debt-to-Equity | N/A | 2.38 | N/A | 0.40 | N/A | N/A | 1.52-1.6x | 3.16+1.5x | 1.69+0.7x | 0.94+0.5x | 0.49 | N/A | N/A |
| FCF Margin | -306.3% | -552.4% | -99.8% | -259.5% | -274.5% | N/A | N/A | -4182.4% | N/A | -7105.3% | -1312.7% | -1011.5% | N/A |
Not reported in any period shown, so not listed: Gross Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Note: Shareholder equity is negative (-$27.9M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Similar Companies
Where Carisma Therapeutics Inc Ranks
Frequently Asked Questions
What is Carisma Therapeutics Inc's annual revenue?
Carisma Therapeutics Inc (CARM) reported $19.6M in total revenue for fiscal year 2024. This represents a 31.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Carisma Therapeutics Inc's revenue growing?
Carisma Therapeutics Inc (CARM) revenue grew by 31.5% year-over-year, from $14.9M to $19.6M in fiscal year 2024.
Is Carisma Therapeutics Inc profitable?
No, Carisma Therapeutics Inc (CARM) reported a net income of -$60.5M in fiscal year 2024.
What is Carisma Therapeutics Inc's EBITDA?
Carisma Therapeutics Inc (CARM) had EBITDA of -$58.8M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Carisma Therapeutics Inc's free cash flow?
Carisma Therapeutics Inc (CARM) recorded an outflow of $60.0M in free cash flow during fiscal year 2024. This represents a 27.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Carisma Therapeutics Inc's operating cash flow?
Carisma Therapeutics Inc (CARM) recorded an outflow of $59.9M in operating cash flow during fiscal year 2024, representing cash used by core business activities.
What are Carisma Therapeutics Inc's total assets?
Carisma Therapeutics Inc (CARM) had $30.5M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Carisma Therapeutics Inc's capital expenditures?
Carisma Therapeutics Inc (CARM) invested $123K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Carisma Therapeutics Inc spend on research and development?
Carisma Therapeutics Inc (CARM) invested $59.7M in research and development during fiscal year 2024.
What is Carisma Therapeutics Inc's current ratio?
Carisma Therapeutics Inc (CARM) had a current ratio of 1.48 as of fiscal year 2024, which is considered adequate.
What is Carisma Therapeutics Inc's return on assets (ROA)?
Carisma Therapeutics Inc (CARM) had a return on assets of -198.6% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
Why is Carisma Therapeutics Inc's debt-to-equity ratio negative or not reported?
Carisma Therapeutics Inc (CARM) has negative shareholder equity of -$27.9M as of fiscal year 2024, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Carisma Therapeutics Inc's Piotroski F-Score?
Carisma Therapeutics Inc (CARM) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Carisma Therapeutics Inc's earnings high quality?
Carisma Therapeutics Inc (CARM) reported a net loss of $60.5M while operations used $59.9M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.